These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38772391)

  • 1. Is Stimulated Thyroglobulin Before Radioiodine Therapy a Useful Tool in Predicting Response to Initial Therapy in Patients with Differentiated Thyroid Carcinoma?
    Jaeger F; Eidt LB; Guidolin K; Landenberger GMC; Bündchen C; Golbert L; Mattevi VS; Meyer ELS
    Horm Metab Res; 2024 Sep; 56(9):641-648. PubMed ID: 38772391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influencing Factors of Urinary Iodine Concentration Before and After Radioiodine Therapy for Differentiated Thyroid Cancer: An Initial Exploration of the Relationship With Therapeutic Efficacy.
    Liu Q; Zhou H; Xia Y; Huang Y; Liu L; Jiang X; Shi Y
    Cancer Control; 2024; 31():10732748241292786. PubMed ID: 39405376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma.
    Keshavarzi A; Alaei-Shahmiri F; Fallahi B; Emami Z; Malek M; Khamseh ME
    BMC Endocr Disord; 2024 Jul; 24(1):112. PubMed ID: 39004697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
    Wang C; Zhang X; Li H; Li X; Lin Y
    PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer.
    Ledwon A; Paliczka-Cieślik E; Syguła A; Olczyk T; Kropińska A; Kotecka-Blicharz A; Hasse-Lazar K; Kluczewska-Gałka A; Jarząb B; Handkiewicz-Junak D
    Ann Nucl Med; 2021 Nov; 35(11):1214-1222. PubMed ID: 34363597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma.
    Parvathareddy SK; Siraj AK; Ahmed SO; Annaiyappanaidu P; Al-Rasheed M; Al-Haqawi W; Qadri Z; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Endocrine; 2024 Oct; 86(1):268-275. PubMed ID: 38696058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
    Zhao T; Liang J; Guo Z; Li J; Lin Y
    Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
    Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
    Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma.
    Wang C; Zhang R; Wang R; Meng Z; Zhang G; Dong F; He Y; Tan J
    Front Endocrinol (Lausanne); 2021; 12():667544. PubMed ID: 34040584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
    Wang C; Zhao T; Li H; Gao W; Lin Y
    Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
    Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
    Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in children and adolescents with differentiated thyroid cancer treated with total thyroidectomy and radioiodine therapy: a retrospective two-center study from China.
    Wang C; Li Y; Wang G; Liu X; Zhang Y; Lu C; Li J; Han N; Wang Z; Si Z; Li F; Lu G; Wang R; Wang X
    Front Endocrinol (Lausanne); 2024; 15():1419141. PubMed ID: 39104809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.